Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Monath

Showing results (91-100 of 136) with videos related to

Pageof 14
Sort By:
The American Journal of Tropical Medicine and Hygiene|December 1, 2004
Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic toolKonstantin V Pugachev, Farshad Guirakhoo, Fred Mitchell, et al.
The Journal of Infectious Diseases|June 20, 2022
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine BoosterFarshad Guirakhoo, Shixia Wang, Chang Yi Wang, et al.
Vaccine|September 10, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccinesRichard C Condit, Denny Kim, James S Robertson, et al.
The Journal of Infectious Diseases|November 1, 2003
Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapyGiselle Soto, Christian T Bautista, Daniel E Roth, et al.
Frontiers in Immunology|September 21, 2023
Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus diseaseThomas P Monath, Richard Nichols, Friederike Feldmann, et al.
Journal of Fungi (Basel, Switzerland)|August 26, 2022
Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human TrialsJohn N Galgiani, Lisa F Shubitz, Marc J Orbach, et al.
Human Vaccines|October 3, 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypesFarshad Guirakhoo, Scott Kitchener, Dennis Morrison, et al.
Vaccine|June 24, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccinesDenny Kim, James S Robertson, Jean-Louis Excler, et al.
The Lancet. Infectious Diseases|June 14, 2017
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response studyD Gray Heppner, Tracy L Kemp, Brian K Martin, et al.
Biologicals : Journal of the International Association of Biological Standardization|June 25, 2005
Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeysThomas P Monath, Gwendolyn A Myers, Robert A Beck, et al.
Pageof 14

Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
The American Journal of Tropical Medicine and Hygiene|December 1, 2004
Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic toolKonstantin V Pugachev, Farshad Guirakhoo, Fred Mitchell, et al.
The Journal of Infectious Diseases|June 20, 2022
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine BoosterFarshad Guirakhoo, Shixia Wang, Chang Yi Wang, et al.
Vaccine|September 10, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccinesRichard C Condit, Denny Kim, James S Robertson, et al.
The Journal of Infectious Diseases|November 1, 2003
Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapyGiselle Soto, Christian T Bautista, Daniel E Roth, et al.
Frontiers in Immunology|September 21, 2023
Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus diseaseThomas P Monath, Richard Nichols, Friederike Feldmann, et al.
Journal of Fungi (Basel, Switzerland)|August 26, 2022
Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human TrialsJohn N Galgiani, Lisa F Shubitz, Marc J Orbach, et al.
Human Vaccines|October 3, 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypesFarshad Guirakhoo, Scott Kitchener, Dennis Morrison, et al.
Vaccine|June 24, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccinesDenny Kim, James S Robertson, Jean-Louis Excler, et al.
The Lancet. Infectious Diseases|June 14, 2017
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response studyD Gray Heppner, Tracy L Kemp, Brian K Martin, et al.
Biologicals : Journal of the International Association of Biological Standardization|June 25, 2005
Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeysThomas P Monath, Gwendolyn A Myers, Robert A Beck, et al.
Pageof 14